MY130957A - Triazine derivatives and their application as antitelomerase agents - Google Patents
Triazine derivatives and their application as antitelomerase agentsInfo
- Publication number
- MY130957A MY130957A MYPI20021036A MYPI20021036A MY130957A MY 130957 A MY130957 A MY 130957A MY PI20021036 A MYPI20021036 A MY PI20021036A MY PI20021036 A MYPI20021036 A MY PI20021036A MY 130957 A MY130957 A MY 130957A
- Authority
- MY
- Malaysia
- Prior art keywords
- agents
- antitelomerase
- application
- triazine derivatives
- relates
- Prior art date
Links
- 150000003918 triazines Chemical class 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0103916A FR2822468B1 (fr) | 2001-03-23 | 2001-03-23 | Derives chimiques et leur application comme agent anti-telomerase |
| FR0110370 | 2001-08-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY130957A true MY130957A (en) | 2007-07-31 |
Family
ID=26212933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20021036A MY130957A (en) | 2001-03-23 | 2002-03-22 | Triazine derivatives and their application as antitelomerase agents |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1373252A1 (enExample) |
| JP (1) | JP2004524349A (enExample) |
| AR (1) | AR034297A1 (enExample) |
| AU (1) | AU2002251140B2 (enExample) |
| CA (1) | CA2442012A1 (enExample) |
| CO (1) | CO5380035A1 (enExample) |
| IL (2) | IL158056A0 (enExample) |
| MX (1) | MXPA03008269A (enExample) |
| MY (1) | MY130957A (enExample) |
| PE (1) | PE20020959A1 (enExample) |
| WO (1) | WO2002076975A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002314252A1 (en) * | 2001-05-28 | 2002-12-09 | Aventis Pharma S.A. | Chemical derivatives and the use thereof as an anti-telomerase agent |
| US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
| AU2002361846A1 (en) * | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| WO2004001018A2 (en) * | 2002-06-25 | 2003-12-31 | The Center For Blood Research, Inc. | Vacuolins |
| FR2850970B1 (fr) * | 2003-02-07 | 2006-07-07 | Aventis Pharma Sa | Derives chimiques se liant de maniere tres specifique aux structures d'adn en g-quadruplexe et leur application comme agent anticancereux specifique |
| AU2004253967B2 (en) | 2003-07-03 | 2010-02-18 | Cytovia, Inc. | 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| EP1833482A4 (en) | 2005-01-03 | 2011-02-16 | Myriad Genetics Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2608463C (en) * | 2005-05-19 | 2015-02-03 | Prometic Biosciences Inc. | Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers |
| EP2046763A2 (en) * | 2006-07-31 | 2009-04-15 | Praecis Pharmaceuticals Incorporated | Aurora kinase inhibitors from an encoded small molecule library |
| KR20100038108A (ko) * | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| FR2948686B1 (fr) * | 2009-07-30 | 2011-08-19 | Biomerieux Sa | Nouveaux substrats de peptidase |
| US20210024455A1 (en) * | 2018-03-20 | 2021-01-28 | Hiroshima University | Compound which inhibits telomere-binding protein, and telomere-binding protein inhibitor containing same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206768D0 (en) * | 1992-03-27 | 1992-05-13 | Jarman Michael | New compounds for use in the treatment of cancer |
| JPH1160573A (ja) * | 1997-08-22 | 1999-03-02 | Nippon Kayaku Co Ltd | トリアジン誘導体及びテロメラーゼ阻害剤 |
| US6262053B1 (en) * | 1999-06-23 | 2001-07-17 | Parker Hughes Institute | Melamine derivatives as potent anti-cancer agents |
| IL149402A0 (en) * | 1999-11-29 | 2002-11-10 | Aventis Pharma Sa | Arylamine derivatives and their use as anti-telomerase agent |
| AU2003244463A1 (en) * | 2002-02-05 | 2003-09-02 | Yamanouchi Pharmaceutical Co., Ltd. | 2,4,6-triamino-1,3,5-triazine derivative |
-
2002
- 2002-03-21 CO CO02025874A patent/CO5380035A1/es not_active Application Discontinuation
- 2002-03-22 AR ARP020101060A patent/AR034297A1/es unknown
- 2002-03-22 CA CA002442012A patent/CA2442012A1/fr not_active Abandoned
- 2002-03-22 WO PCT/FR2002/001005 patent/WO2002076975A1/fr not_active Ceased
- 2002-03-22 IL IL15805602A patent/IL158056A0/xx unknown
- 2002-03-22 JP JP2002576233A patent/JP2004524349A/ja not_active Ceased
- 2002-03-22 PE PE2002000227A patent/PE20020959A1/es not_active Application Discontinuation
- 2002-03-22 AU AU2002251140A patent/AU2002251140B2/en not_active Ceased
- 2002-03-22 MX MXPA03008269A patent/MXPA03008269A/es not_active Application Discontinuation
- 2002-03-22 MY MYPI20021036A patent/MY130957A/en unknown
- 2002-03-22 EP EP02720068A patent/EP1373252A1/fr not_active Withdrawn
-
2003
- 2003-09-22 IL IL158056A patent/IL158056A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL158056A0 (en) | 2004-03-28 |
| IL158056A (en) | 2010-02-17 |
| JP2004524349A (ja) | 2004-08-12 |
| AU2002251140B2 (en) | 2007-03-15 |
| AR034297A1 (es) | 2004-02-18 |
| MXPA03008269A (es) | 2004-10-15 |
| PE20020959A1 (es) | 2002-12-17 |
| CA2442012A1 (fr) | 2002-10-03 |
| EP1373252A1 (fr) | 2004-01-02 |
| CO5380035A1 (es) | 2004-03-31 |
| WO2002076975A1 (fr) | 2002-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL149402A0 (en) | Arylamine derivatives and their use as anti-telomerase agent | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| DE60112974D1 (en) | Carbolinderivate | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
| TNSN04113A1 (en) | 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| MY130957A (en) | Triazine derivatives and their application as antitelomerase agents | |
| EP1432714A4 (en) | CHEMICAL COMPOUNDS | |
| TW200510325A (en) | 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
| MY128924A (en) | Novel compounds | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| MXPA04003796A (es) | Tioacetamidas sustituidas. | |
| DE60216233D1 (en) | Carbolinderivate | |
| HUP0500424A2 (en) | Combination therapy for the treatment of cancer | |
| MXPA03010761A (es) | Combinaciones farmaceuticas. | |
| MXPA03008634A (es) | Nuevos compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades. | |
| PT1463735E (pt) | Imidazo-2,1-b-1,3,4-tiadiazol sulfonamidas | |
| YU8804A (sh) | Jedno-dozni azitromicin | |
| GB0018951D0 (en) | Novel compounds | |
| GB0215526D0 (en) | Anticancer compounds | |
| EP1303520A4 (en) | THERAPEUTIC COMPOUNDS AND METHODS | |
| MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
| IL161116A0 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
| AU2001280754A1 (en) | Enhancement of photodynamic therapy by anti-angiogenic treatment | |
| EP1436279A4 (en) | CHEMICAL COMPOUNDS |